Question Bank › Reporting the counterparty's growth as its own

Reporting the counterparty's growth as its own

Reporting the counterparty's growth as its own: management explains the company's coming year by narrating what its cust

Calls Tested
495
Answered YES
10
Hit Rate
2%
rare by design

OPKO Health, Inc. (OPK) — this company's answers

NO on the Q1 2022 call 2022-05-09 D
The model's full reasoning — Q1 2022 call → NOWe need to determine if management's forward account is substantially about counterparties' own growth/expansion, with the company already embedded, and the trajectory early and large. Key parts: - Pfizer launching Neglina (Somatrogon) in Germany, Japan, Canada, Australia. Milestones triggered. But is this about Pfizer's own scaling? Management mentions launches and milestones, but not detailed ramp of Pfizer's own activities. It's more about regulatory approvals and milestones. - Sema4 acquisition of GeneDx: This is about divesting GeneDx, not about counterparty growth driving OPKO's business. - BioReference: mentions commercial payer interactions (Aetna, UnitedHealthcare) preferred status, but that's about contracts, not about those payers' own expansion. Mentions Scarlet Health with Teladoc and MVP Healthcare - Teladoc is a telehealth provider, but management says "Scarlet is now offered by Teladoc Health as part of their new whole person health care experience." That is a partnership, but does management describe Teladoc's own scaling? Not really. It's just an agreement. - COVID testing: mentions schools, cruise lines, sports industry. But that's general, not specific counterparties' build-out. - The ModeX acquisition: that's about internal R&D, not counterparties. The question asks: does management explain where the company's business is going by narrating what its counterparties are themselves doing and scaling? The key is whether a substantial part of the forward account consists of reporting on the growth of specific customers/partners that the company already supplies, such that the company's volume is a consequence of those parties' trajectories. Looking at the transcript: - Pfizer launches: "Pfizer recently launched Neglina in the major markets of Germany and Japan as well as in Canada and Australia." That's about Pfizer's actions, but it's not about scaling up over time. It's just a launch event. Also, "Pfizer is continuing to work with the FDA to resolve any remaining issues" - that's about regulatory, not scaling. - The $85 million milestone is a one-time payment, not a ramp. - For BioReference, they mention "preferred status with Aetna" and "UnitedHealthcare" - but that's about contracts, not about those payers' own expansion. They don't describe Aetna or UnitedHealthcare building out networks or adding members.

← Back to the full OPK analysis

Show the exact prompt the model was given
Using ONLY the supplied earnings call transcript and no outside information: On this call, does management explain where the company's business is going by NARRATING WHAT ITS COUNTERPARTIES ARE THEMSELVES DOING AND SCALING — that is, does a substantial part of management's forward account consist of reporting on the growth, expansion, ramp, adoption, or program build-out of specific customers, partners, licensees, distributors, payers, operators, or programs the company ALREADY SUPPLIES OR SERVES, such that the company's own coming volume is presented as a consequence of those parties' own trajectories rather than of the company's selling effort? Answer YES when management's own words convey, in whatever form fits the industry, ONE coherent posture in which all three of the following come through as a present-tense reality: (1) MANAGEMENT SPEAKS ABOUT ITS COUNTERPARTIES' BUSINESS AS THOUGH IT WERE PART OF ITS OWN. In explaining the company's outlook, management devotes real substance to describing what identifiable counterparties are up to — their own ramps, launches, rollouts, capacity additions, adoption curves, program phases, store or site build-outs, production schedules, market entries, or spending plans — and treats those trajectories as the driver of the company's coming activity. The counterparties may be named or described unmistakably ("our lead customer," "the large operator we supply," "the national program we participate in"), and may be one dominant party or a small set. What matters is the DIRECTION OF EXPLANATION: management is reporting on somebody else's growth as the reason for its own, and speaks about that other party's plans with the familiarity of an insider to them. (2) THE COMPANY IS ALREADY INSIDE THAT GROWTH, NOT BIDDING FOR IT. Management makes clear the company is already supplying, serving, embedded in, specified into, or contracted to those counterparties — real current activity flowing today (shipments, deliveries, work performed, product in use, volumes recognized) — so the demand question is settled and what remains is how far the counterparties' own trajectories carry the company. Interest, pipeline, prospects being courted, bids outstanding, or relationships still contingent on approvals or decisions do NOT satisfy this. (3) THE COUNTERPARTIES' TRAJECTORY IS EARLY AND LARGE RELATIVE TO THE COMPANY. Management conveys, directly or plainly in substance, that these parties are still in the early or intensifying part of what they are doing — more phases, sites, volumes, regions, or years ahead — and that what has reached the company so far is small relative to what their continued growth implies, so the results just reported reflect the company before that growth arrives. Management may express this by discussing how it is preparing capacity or staffing for volumes not yet arriving, by contrasting today's contribution against the counterparties' stated plans, or by describing which phase of the counterparties' build-out is now beginning. The essence is ONE phenomenon: a company whose forward story has become a report on somebody else's expansion, where the decision to use this company is already made, the money is already flowing, and the expansion is young. The industry, the counterparty type, and what the company provides may vary widely. Answer NO if management explains its outlook chiefly through its own actions — new products, selling effort, marketing, pricing, capacity additions, cost programs, share gains — or through broad market, industry, or macro conditions, without narrating identifiable counterparties' own trajectories. NO if the counterparties described are prospects, targets, or parties the company hopes to win rather than ones it already serves. NO if the counterparties' activity is described as flat, mature, decelerating, being digested, at risk, or being renegotiated downward. NO if the company's participation in that activity is already fully reflected in reported results, with no meaningful ramp ahead. NO if the counterparty relationship is discussed only as a concentration risk, a source of lumpiness, or a passing statistic without its trajectory governing the forward account. NO if the company is large or diversified enough that these counterparties' growth would not visibly change its trajectory. NO if management merely reports strong demand from customers generally, without describing what specific counterparties are themselves building or scaling. NO if the counterparties' plans appear only in an analyst's question or characterization that management does not itself affirm. Use only the supplied transcript. Answer only YES or NO.

Companies that answered YES

TickerCompanyCallDateCall grade
EMKR EMCORE Corporation Q4 2023 2023-12-12 C+
MBLY Mobileye Global Inc. Q2 2023 2023-07-28 B+
PI Impinj, Inc. Q4 2022 2023-02-08 B+
FAT FAT Brands Inc. Q4 2021 2022-03-21 F
OOMA Ooma, Inc. Q3 2022 2021-12-02 B+
ILMN Illumina, Inc. Q1 2018 2018-04-24 A
PLAB Photronics, Inc. Q2 2017 2017-05-17 C+
IONS Ionis Pharmaceuticals, Inc. Q1 2017 2017-05-09 C
FNV Franco-Nevada Corporation Q3 2016 2016-11-08 B+
HXL Hexcel Corporation Q4 2015 2016-01-22 B+

How the model reasoned

OOMA · Q3 2022 → YESThe question is about whether management narrates what its counterparties are doing and scaling, presenting the company's future volume as a consequence of those parties' trajectories.
MBLY · Q2 2023 → YESThe question is about whether management narrates what its counterparties are doing and scaling, presenting the company's volume as a consequence of those parties' trajectories.
ILMN · Q1 2018 → YESThe question is about whether management narrates what its counterparties are doing and scaling, presenting the company's future as a consequence of those parties' trajectories.

More from the question bank

The feared thing keeps not happeningNew normal declared and staffedDoors opening at the company's own gatesDemand arrived first, the company is growingSecond proving already underwayRacing a clock somebody else setAll questions →
Not investment advice. Artul.ai publishes AI-generated earnings-call quality grades and expected-volatility estimates — never buy or sell recommendations. We tested over 1,600 predictive hypotheses against 165,000 transcripts; the honest result, including what failed, is documented in our methodology.